Gene · 2877
Papers1,817
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,817
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| GPX2 induces macrophage M2 polarization through the MIF signaling pathway to promote colorectal cancer progression. | Int J Biol Macromol | 2025 | 41106750 | PubTator, text mining | PubMed |
| Transcriptome analysis of five-toed jerboa organs reveals high-altitude adaptation mechanisms. | BMC Genomics | 2025 | 41057799 | PubTator, text mining | PubMed |
| Oxidative Stress and Antioxidant Therapies in Friedreich's Ataxia. | Cells | 2025 | 41002373 | PubTator, text mining | PubMed |
| N6-Methyladenosine-Modified circNEK11 Promotes Hepatocellular Carcinoma Progression via the miR-1236-3p/GPX2 Axis. | Cancer Sci | 2025 | 40990491 | PubTator, text mining | PubMed |
| Hidden markers of health: how mercury affects gene expression in developing seabirds. | Environ Pollut | 2025 | 40983176 | PubTator, text mining | PubMed |
| Impact of zinc oxide on gut health, immunity, and growth in weaned piglets: exploring potential modes of action. | Front Vet Sci | 2025 | 40959845 | PubTator, text mining | PubMed |
| Organic-inorganic covalent selenium reversing ischemic reperfusion injury. | Nat Commun | 2025 | 40877267 | PubTator, text mining | PubMed |
| Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers. | Mol Cancer | 2025 | 40847302 | PubTator, text mining | PubMed |
| Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer. | NPJ Precis Oncol | 2025 | 40825842 | PubTator, text mining | PubMed |
| Multi-omics integration reveals functional signatures of gut microbiome in atherosclerosis. | Gut Microbes | 2025 | 40785047 | PubTator, text mining | PubMed |
| Sphingosine-1-phosphate alleviates colitis by regulating macrophage polarization and PI3k-Akt signaling. | Front Immunol | 2025 | 40761802 | PubTator, text mining | PubMed |
| PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment. | MedComm (2020) | 2025 | 40740483 | PubTator, text mining | PubMed |
| The Role of GPX Enzymes, Lipid Profiles, and Iron Accumulation in Necrotizing Enterocolitis. | Int J Mol Sci | 2025 | 40649855 | PubTator, text mining | PubMed |
| Human milk metabolites modulate gut barrier and immunity-related genes in an in vitro multicellular model of intestinal epithelium. | Food Funct | 2025 | 40538378 | PubTator, text mining | PubMed |
| N6-methyladenosine-modified GPX2 impacts cancer cell stemness and TKI resistance through regulating of redox metabolism. | Cell Death Dis | 2025 | 40533443 | PubTator, text mining | PubMed |
| Integrative single-cell RNA sequencing and bulk RNA sequencing reveals the characteristics of glutathione metabolism and protective role of GSTA4 gene in pancreatic cancer. | Front Immunol | 2025 | 40375987 | PubTator, text mining | PubMed |
| Unveiling the Cuproptosis in Colitis and Colitis-Related Carcinogenesis: A Multifaceted Player and Immune Moderator. | Research (Wash D C) | 2025 | 40370501 | PubTator, text mining | PubMed |
| GPX2 inhibition enhances antitumor efficacy of lenvatinib via promoting immunogenic cell death in hepatocellular carcinoma. | J Transl Med | 2025 | 40251668 | PubTator, text mining | PubMed |
| X-ray-Sensitive Selenium Nanoparticles Enhance Esophageal Squamous Cell Carcinoma Radiotherapy through Activating P53/IGFBP3 Pathway by Regulating GPX2. | ACS Appl Mater Interfaces | 2025 | 40241246 | PubTator, text mining | PubMed |
| Integrative analysis of a novel signature incorporating metabolism and stemness-related genes for risk stratification and assessing clinical outcomes and therapeutic responses in lung adenocarcinoma. | BMC Cancer | 2025 | 40170009 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2877/papers?page=3